Shawn Iadonato

Kineta, Inc.

$3,680,642

Attributed

$3,680,642

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.8M · FY2015–17

$2M$1.5M$1M$500K$0

'15

'16

'17

Funding mix

By agency

NIH$3,680,642 · 1

By mechanism

N01$3,680,642 · 1

Top collaborators

No co-investigators on record.

Most similar at Kineta, Inc.

Same institution · by research overlap

Others in their field

Top investigators on “Pre-Clinical”

Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
Dennis R. Burton · Scripps Research Institute$257,157,696
Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
Barton F Haynes · Duke University$186,001,832
David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
Reisa A. Sperling · Banner Health$137,047,788

Research focus

Pre-ClinicalSmall MoleculeSeriesTherapeutic DevelopmentFutureInfectious Disease TreatmentToxic EffectCommunicable DiseasesDrug CandidateIn VitroIn VivoLeadPharmaceutical ChemistryStagingClinical DevelopmentDengueInfluenza A Virus, H1n1 SubtypeInfluenza TherapeuticInfluenza A VirusZika Virus

Grant awards (6)

Optimizing Lead Therapeutic Compounds Against Infectious Diseases$239,962

N01 · FY2017 · AI · contact PI

Optimizing Lead Therapeutic Compounds Against Infectious Diseases$239,961

N01 · FY2017 · AI · contact PI

Optimizing Lead Therapeutic Compounds Against Infectious Diseases$641,709

N01 · FY2016 · AI · contact PI

Optimizing Lead Therapeutic Compounds Against Infectious Diseases$641,708

N01 · FY2016 · AI · contact PI

Optimizing Lead Therapeutic Compounds Against Infectious Diseases$499,380

N01 · FY2016 · AI · contact PI

Optimizing Lead Therapeutic Compounds Against Infectious Diseases$1,417,922

N01 · FY2015 · AI · contact PI